Locations:
Search IconSearch
October 25, 2022/Cancer/Research

Biosignature Tool Predicts Individual’s Benefit from Radiation Therapy Following Breast-Conserving Therapy

Use of tool can change recommendation to add or omit radiation

22-CNR-3290413-CQD-Hero-650×450 DCIS

Incorporating a seven-gene assay with a novel biosignature (DCISionRT) is superior to clinicopathologic risk assessment alone in estimating the ten-year risk of recurrence for patients with ductal carcinoma in situ (DCIS) following breast conserving surgery as well as predicting benefit from radiation therapy.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Examining recurrence risk factors

“The risk of recurrence in patients with low-risk DCIS is 10 to 20% at 10 to 15 years post lumpectomy without radiation therapy,” says Chirag Shah, MD, Director of Breast Radiation Oncology and Director of Clinical Research-Radiation Oncology at Cleveland Clinic. “We traditionally use factors such as patient age, tumor size, margin status and tumor grade to define that risk. The problem we run into is that patients who are considered as having low recurrence risk, based on factors such as low-grade disease, smaller tumor size and negative margins, still have elevated rates of recurrence when radiation is omitted. In studies comparing radiation and no radiation, even these low-risk patients derive a benefit from radiation, which informs us that we haven’t been able to pick out the group that does not benefit from radiation using traditional clinicopathologic features.”

In contrast, the biosignature combines biomarkers and four clinicopathologic factors to assess individual tumor biology, providing a personalized recurrence risk. In the analysis, 926 women from four cohorts who were treated with BCS with negative margins, with or without adjuvant radiation, had a decision score calculated using DCISionRT. Based on their score, patients were classified as either low risk, elevated risk or residual risk. Dr. Shah presented the findings at the 2022 American Society for Radiation Oncology meeting.

Residual risk group: three-times greater rate of recurrence

The low-risk group, approximately 37% of all patients, were found not to derive a benefit from adjuvant radiation with respect to ten-year recurrence rates. The elevated-risk group, which represented about 43% of patients, experienced a significant benefit from radiation therapy, with the risk of recurrence declining from 21% to about 5% with the addition of radiation therapy, corresponding to an 80% reduction in risk (P<0.001). The benefit persisted even in those patients with good clinicopathologic features who were to have elevated risk DCISionRT scores.

Advertisement

“The final group, the 20% of patients with residual risk, were found to benefit from adjuvant radiation (42% vs. 15%) but still had elevated rates of recurrence even after treatment. This was a major finding of the study,” says Dr. Shah. “There are some patients we treat with all standard treatment and yet they still have a recurrence. We have to figure out who these patients are. The residual risk group makes up a small percentage of the total number of patients, but they had almost a 15% rate of recurrence even after lumpectomy and radiation, compared with 5% in the other groups, a three-fold higher risk.”

Additionally, Dr. Shah and colleagues previously found that the information provided by DCISionRT often changed recommendations to add or omit radiation therapy following breast-conserving surgery in patients with DCIS—approximately of 40% patients had a change in radiation therapy recommendation (46% from recommending radiation therapy to omitting radiation, and 35% from omitting to adding radiation).

DCISionRT is offered in clinical practice at Cleveland Clinic, where research on its clinical utility continues.

Advertisement

Related Articles

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Lung cancer cells
June 5, 2024/Cancer/Research
Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

cancer cells
June 4, 2024/Cancer/Research
Researchers Identify Tumor Microbiome Differences in Early- vs. Average-Onset Pancreatic Adenocarcinoma

Further study warranted to better understand the clinical implications of these findings

car T-cells
June 3, 2024/Cancer/Research
CAR T-Cell Treatment Offers Hope for Richter Transformation

Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel

Blood clot
May 17, 2024/Cancer/Research
Managing the Risks of Venous Thromboembolisms in Patients with Cancer

Oral anticoagulants may be beneficial but need to be balanced against bleeding risks

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Ad